CITIUS ONCOLOGY, INC.

TenX Keane Acquisition Corp. (Nasdaq: TENK), sponsored by TenX Capital Management, was a blank check company that completed its initial public offering in 2022 targeting the healthcare and biopharmaceutical sector. The SPAC announced a business combination with Citius Oncology, Inc. in October 2023, bringing together the shell vehicle and a commercial-stage oncology company focused on hospital-based cancer therapeutics. Citius Oncology, which had been spun out from Citius Pharmaceuticals, held rights to FDA-approved oncology treatments at the time of the merger. The transaction has since closed, giving Citius Oncology a public market listing. Visit SpacDesk and sign up for full access to TENK's complete filing history, deal timeline, and comparable SPAC transaction data.

SPAC Counterparty (1)